Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056037 | 0.86 | LMNA (0.53) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL3050849 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL3056073 | 0.80 | GAA (0.47) | ALDH1A1KMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL3059769 | 0.79 | LMNA (0.46) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL3056414 | 0.79 | MEN1 (0.48) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL3139348 | 0.76 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL3128809 | 0.75 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL3051007 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL3138268 | 0.73 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL3147424 | 0.73 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | ALDH1A1 741/4885KMT2A 2904/4885MEN1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.